Hence, rather than being frequently involved in the leukemic progression of SCN, the CXXC4-ITD mutation should be taken as evidence that downregulation of TET2 and the associated upregulation of inflammatory signaling contribute to malignant transformation in conjunction with the CSF3R and RUNX1 mutations. The gene discussed is TET2; the disease is severe congenital neutropenia.